{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T12:42:08Z","timestamp":1792759328149,"version":"4.5.0"},"reference-count":40,"publisher":"American Medical Association (AMA)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"\n Importance<\/jats:title>\n Type 2 diabetes (T2D) and liver cirrhosis frequently coexist, creating a high-risk population for adverse outcomes. Patients with both conditions face elevated risks of kidney and cardiovascular complications, yet evidence regarding optimal antidiabetic therapy in this vulnerable population remains limited.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To evaluate the association of sodium-glucose cotransporter\u20132 inhibitor (SGLT2i) vs dipeptidyl peptidase\u20134 inhibitor (DPP4i) use with kidney outcomes, cardiovascular events, and hepatic decompensation in patients with concurrent T2D and liver cirrhosis.<\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n This nationwide retrospective cohort study utilized data from the Taiwan\u2019s National Health Insurance Database between May 2016 and December 2023. Adults with both T2D and liver cirrhosis who initiated either SGLT2is or DPP4is were included.<\/jats:p>\n <\/jats:sec>\n \n Exposure<\/jats:title>\n Use of SGLT2is (dapagliflozin, empagliflozin, and canagliflozin) or DPP4is (alogliptin, linagliptin, sitagliptin, saxagliptin, and vildagliptin).<\/jats:p>\n <\/jats:sec>\n \n Main Outcomes and Measures<\/jats:title>\n The primary outcomes were end-stage kidney disease (ESKD), acute kidney injury (AKI), and major adverse cardiovascular events (MACE). Secondary outcomes included individual MACE components and hepatic decompensation events. Inverse probability of treatment weighting was employed to balance baseline characteristics.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n Among 24\u202f259 patients (mean [SD] age, 64.68 [11.95] years; 8229 female [33.92%]), 9689 (39.94) received SGLT2is and 14\u202f570 (60.06%) received DPP4is. During a median (IQR) follow-up of 2.3 (1.0-4.0) years, compared with DPP4i use, SGLT2i treatment was associated with significantly reduced risks of ESKD (adjusted hazard ratio [HR], 0.34; 95% CI, 0.25-0.47), AKI (adjusted HR, 0.66; 95% CI, 0.59-0.74), and MACE (adjusted HR, 0.67; 95% CI, 0.62-0.71). Additionally, SGLT2i use was associated with a lower risk of all-cause mortality (adjusted HR, 0.58; 95% CI, 0.53-0.63) and hepatic decompensation events (adjusted HR, 0.65; 95% CI, 0.57-0.74).<\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n In this cohort study of patients with T2D and liver cirrhosis, the use of SGLT2is was associated with substantially lower risks of adverse kidney, cardiovascular, and hepatic outcomes compared with DPP4is. These findings suggested significant cardiorenal and hepatic protection for SGLT2is in this high-risk population.<\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2025.60429","type":"journal-article","created":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T16:30:29Z","timestamp":1771864229000},"page":"e2560429","source":"Crossref","is-referenced-by-count":7,"title":["SGLT2 Inhibitor Use and Cardiorenal Outcomes in Type 2 Diabetes With Liver Cirrhosis"],"prefix":"10.1001","volume":"9","author":[{"given":"Mu-Chi","family":"Chung","sequence":"first","affiliation":[{"name":"Division of Nephrology, Department of Medicine, Taichung Veterans General Hospital, Taichung, Taiwan"},{"name":"Division of Clinical Toxicology, Department of Medical Toxicology, Taichung Veterans General Hospital, Taichung, Taiwan"},{"name":"Department of Post-Baccalaureate Medicine, College of Medicine, National Chung Hsing University, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tung-Min","family":"Yu","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Department of Medicine, Taichung Veterans General Hospital, Taichung, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laing-You","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Public Health, College of Public Health, China Medical University, Taichung, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming-Ju","family":"Wu","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Department of Medicine, Taichung Veterans General Hospital, Taichung, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeng-Jer","family":"Shieh","sequence":"additional","affiliation":[{"name":"Department of Post-Baccalaureate Medicine, College of Medicine, National Chung Hsing University, Taiwan"},{"name":"Institute of Biomedical Sciences, National Chung Hsing University, Taichung, Taiwan"},{"name":"Department of Education and Research, Taichung Veterans General Hospital, Taichung, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chi-Jung","family":"Chung","sequence":"additional","affiliation":[{"name":"Department of Public Health, College of Public Health, China Medical University, Taichung, Taiwan"},{"name":"Department of Medical Research, China Medical University Hospital, Taichung, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2026,2,23]]},"reference":[{"issue":"6","key":"zoi251618r1","doi-asserted-by":"publisher","DOI":"10.1002\/dmrr.3157","article-title":"Prevalence of diabetes in liver cirrhosis: a systematic review and meta-analysis.","volume":"35","author":"Lee","year":"2019","journal-title":"Diabetes Metab Res Rev"},{"issue":"7","key":"zoi251618r2","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1111\/liv.13115","article-title":"Diabetes mellitus in patients with cirrhosis: clinical implications and management.","volume":"36","author":"Elkrief","year":"2016","journal-title":"Liver Int"},{"issue":"11","key":"zoi251618r3","doi-asserted-by":"publisher","first-page":"2611","DOI":"10.1007\/s13300-020-00919-6","article-title":"Impact of liver cirrhosis on incidence of dialysis among patients with type 2 diabetes.","volume":"11","author":"Sheen","year":"2020","journal-title":"Diabetes Ther"},{"issue":"4","key":"zoi251618r4","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1111\/liv.15851","article-title":"Sodium-glucose linked transporter 2 inhibitors in liver cirrhosis: beyond their antidiabetic use.","volume":"44","author":"Siafarikas","year":"2024","journal-title":"Liver Int"},{"issue":"10","key":"zoi251618r5","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1016\/j.amjmed.2007.03.025","article-title":"Impact of diabetes on the severity of liver disease.","volume":"120","author":"Hickman","year":"2007","journal-title":"Am J Med"},{"issue":"11","key":"zoi251618r6","doi-asserted-by":"publisher","DOI":"10.1111\/dme.15437","article-title":"Glucose-lowering drugs and liver-related outcomes among individuals with type 2 diabetes: a systematic review of longitudinal population-based studies.","volume":"41","author":"Khanmohammadi","year":"2024","journal-title":"Diabet Med"},{"issue":"12","key":"zoi251618r7","doi-asserted-by":"publisher","first-page":"2054","DOI":"10.1136\/gutjnl-2024-332481","article-title":"Synergistic association of sodium-glucose cotransporter-2 inhibitor and metformin on liver and non-liver complications in patients with type 2 diabetes mellitus and metabolic dysfunction-associated steatotic liver disease.","volume":"73","author":"Mao","year":"2024","journal-title":"Gut"},{"issue":"6","key":"zoi251618r8","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1016\/j.jfma.2020.04.003","article-title":"2020 Taiwan consensus statement on the management of hepatitis C: part (I) general population.","volume":"119","author":"Yu","year":"2020","journal-title":"J Formos Med Assoc"},{"issue":"8","key":"zoi251618r9","doi-asserted-by":"publisher","first-page":"815","DOI":"10.3390\/v12080815","article-title":"Elimination of hepatitis B in highly endemic settings: lessons learned in Taiwan and challenges ahead.","volume":"12","author":"Liu","year":"2020","journal-title":"Viruses"},{"issue":"3","key":"zoi251618r10","first-page":"157","article-title":"Accuracy of diabetes diagnosis in health insurance claims data in Taiwan.","volume":"104","author":"Lin","year":"2005","journal-title":"J Formos Med Assoc"},{"issue":"19","key":"zoi251618r11","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.118.008982","article-title":"Selection of \u00df-blocker in patients with cirrhosis and acute myocardial infarction: a 13-year nationwide population-based study in Asia.","volume":"7","author":"Wu","year":"2018","journal-title":"J Am Heart Assoc"},{"issue":"1","key":"zoi251618r12","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1093\/aje\/kwu095","article-title":"Cirrhosis as a risk factor for tuberculosis infection\u2013a nationwide longitudinal study in Taiwan.","volume":"180","author":"Lin","year":"2014","journal-title":"Am J Epidemiol"},{"issue":"5","key":"zoi251618r13","doi-asserted-by":"publisher","first-page":"e50","DOI":"10.1097\/MCG.0b013e3182688d2f","article-title":"Use of administrative claims data for identifying patients with cirrhosis.","volume":"47","author":"Nehra","year":"2013","journal-title":"J Clin Gastroenterol"},{"issue":"2","key":"zoi251618r14","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1111\/jth.12805","article-title":"Risks of venous thromboembolism in patients with liver cirrhosis: a nationwide cohort study in Taiwan.","volume":"13","author":"Ng","year":"2015","journal-title":"J Thromb Haemost"},{"issue":"3","key":"zoi251618r15","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1681\/ASN.2013060610","article-title":"Long-term risk of coronary events after AKI.","volume":"25","author":"Wu","year":"2014","journal-title":"J Am Soc Nephrol"},{"issue":"6","key":"zoi251618r16","doi-asserted-by":"publisher","first-page":"500","DOI":"10.2188\/jea.JE20140076","article-title":"Validation of acute myocardial infarction cases in the national health insurance research database in Taiwan.","volume":"24","author":"Cheng","year":"2014","journal-title":"J Epidemiol"},{"issue":"3","key":"zoi251618r17","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1016\/j.jfma.2013.09.009","article-title":"Validating the diagnosis of acute ischemic stroke in a National Health Insurance claims database.","volume":"114","author":"Hsieh","year":"2015","journal-title":"J Formos Med Assoc"},{"issue":"1","key":"zoi251618r18","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1093\/ckj\/sfab158","article-title":"An introduction to inverse probability of treatment weighting in observational research.","volume":"15","author":"Chesnaye","year":"2021","journal-title":"Clin Kidney J"},{"issue":"10","key":"zoi251618r19","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.1002\/sim.6058","article-title":"Metrics for covariate balance in cohort studies of causal effects.","volume":"33","author":"Franklin","year":"2014","journal-title":"Stat Med"},{"issue":"1","key":"zoi251618r20","doi-asserted-by":"publisher","first-page":"16","DOI":"10.21037\/atm.2018.12.10","article-title":"Balance diagnostics after propensity score matching.","volume":"7","author":"Zhang","year":"2019","journal-title":"Ann Transl Med"},{"issue":"2","key":"zoi251618r21","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1002\/pst.433","article-title":"Optimal caliper widths for propensity-score matching when estimating differences in means and differences in proportions in observational studies.","volume":"10","author":"Austin","year":"2011","journal-title":"Pharm Stat"},{"issue":"2","key":"zoi251618r22","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1038\/nrendo.2017.173","article-title":"Nonalcoholic fatty liver disease and chronic vascular complications of diabetes mellitus.","volume":"14","author":"Targher","year":"2018","journal-title":"Nat Rev Endocrinol"},{"issue":"8","key":"zoi251618r23","doi-asserted-by":"publisher","first-page":"2119","DOI":"10.2337\/dc07-0349","article-title":"Nonalcoholic fatty liver disease is independently associated with an increased incidence of cardiovascular events in type 2 diabetic patients.","volume":"30","author":"Targher","year":"2007","journal-title":"Diabetes Care"},{"key":"zoi251618r24","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2021.174272","article-title":"Sodium-glucose co-transporter 2 inhibitors in nonalcoholic fatty liver disease.","volume":"907","author":"Makri","year":"2021","journal-title":"Eur J Pharmacol"},{"issue":"2","key":"zoi251618r25","doi-asserted-by":"publisher","first-page":"82","DOI":"10.36628\/ijhf.2022.0030","article-title":"SGLT-2 Inhibitors in heart failure: a review of current evidence.","volume":"5","author":"Talha","year":"2023","journal-title":"Int J Heart Fail"},{"issue":"5","key":"zoi251618r26","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1016\/j.jhep.2010.11.007","article-title":"Risk of chronic kidney disease in patients with non-alcoholic fatty liver disease: is there a link?","volume":"54","author":"Targher","year":"2011","journal-title":"J Hepatol"},{"key":"zoi251618r27","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.metabol.2017.11.003","article-title":"Nonalcoholic fatty liver disease increases risk of incident chronic kidney disease: a systematic review and meta-analysis.","volume":"79","author":"Mantovani","year":"2018","journal-title":"Metabolism"},{"issue":"6","key":"zoi251618r28","doi-asserted-by":"publisher","first-page":"2064","DOI":"10.1002\/hep.22605","article-title":"Acute kidney injury in cirrhosis.","volume":"48","author":"Garcia-Tsao","year":"2008","journal-title":"Hepatology"},{"issue":"4","key":"zoi251618r29","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1016\/j.jhep.2011.10.016","article-title":"Renal failure and cirrhosis: a systematic review of mortality and prognosis.","volume":"56","author":"Fede","year":"2012","journal-title":"J Hepatol"},{"issue":"10365","key":"zoi251618r30","doi-asserted-by":"publisher","first-page":"1788","DOI":"10.1016\/S0140-6736(22)02074-8","article-title":"Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials.","volume":"400","author":"Nuffield Department of Population Health Renal Studies Group","year":"2022","journal-title":"Lancet"},{"issue":"2","key":"zoi251618r31","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.0453","article-title":"Sodium-glucose transport protein 2 inhibitor use for type 2 diabetes and the incidence of acute kidney injury in Taiwan.","volume":"6","author":"Chung","year":"2023","journal-title":"JAMA Netw Open"},{"issue":"10","key":"zoi251618r32","doi-asserted-by":"publisher","first-page":"2402","DOI":"10.1111\/dom.14488","article-title":"Impact of SGLT2 inhibitors in comparison with DPP4 inhibitors on ascites and death in veterans with cirrhosis on metformin.","volume":"23","author":"Saffo","year":"2021","journal-title":"Diabetes Obes Metab"},{"issue":"5","key":"zoi251618r33","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1007\/s00592-018-1116-0","article-title":"SGLT-2 inhibitors and the risk of infections: a systematic review and meta-analysis of randomized controlled trials.","volume":"55","author":"Puckrin","year":"2018","journal-title":"Acta Diabetol"},{"issue":"12","key":"zoi251618r34","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.1007\/s00535-024-02158-z","article-title":"Effects of SGLT2 inhibitors on the onset of esophageal varices and extrahepatic cancer in type 2 diabetic patients with suspected MASLD: a nationwide database study in Japan.","volume":"59","author":"Kawaguchi","year":"2024","journal-title":"J Gastroenterol"},{"issue":"2","key":"zoi251618r35","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1136\/gutjnl-2024-332687","article-title":"Risk of hepatic events associated with use of sodium-glucose cotransporter-2 inhibitors versus glucagon-like peptide-1 receptor agonists, and thiazolidinediones among patients with metabolic dysfunction-associated steatotic liver disease.","volume":"74","author":"Bea","year":"2025","journal-title":"Gut"},{"issue":"10","key":"zoi251618r36","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1016\/S2468-1253(19)30227-4","article-title":"Global burden of atherosclerotic cardiovascular disease in people with hepatitis C virus infection: a systematic review, meta-analysis, and modelling study.","volume":"4","author":"Lee","year":"2019","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"1","key":"zoi251618r37","doi-asserted-by":"publisher","first-page":"21","DOI":"10.5604\/16652681.1226813","article-title":"Association between hepatitis B virus and chronic kidney disease: a systematic review and meta-analysis.","volume":"16","author":"Fabrizi","year":"2017","journal-title":"Ann Hepatol"},{"issue":"13","key":"zoi251618r38","doi-asserted-by":"publisher","first-page":"3410","DOI":"10.3748\/wjg.v20.i13.3410","article-title":"Chronic hepatitis C virus infection and atherosclerosis: clinical impact and mechanisms.","volume":"20","author":"Adinolfi","year":"2014","journal-title":"World J Gastroenterol"},{"issue":"26","key":"zoi251618r39","doi-asserted-by":"publisher","first-page":"3971","DOI":"10.3748\/wjg.v27.i26.3971","article-title":"Chronic hepatitis B infection with concomitant hepatic steatosis: current evidence and opinion.","volume":"27","author":"Shi","year":"2021","journal-title":"World J Gastroenterol"},{"issue":"5","key":"zoi251618r40","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.1097\/HEP.0000000000000404","article-title":"SGLT2i reduces risk of developing HCC in patients with co-existing type 2 diabetes and hepatitis B infection: a territory-wide cohort study in Hong Kong.","volume":"78","author":"Lee","year":"2023","journal-title":"Hepatology"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2845333\/chung_2026_oi_251618_1772647201.27784.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T18:30:16Z","timestamp":1772649016000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2845333"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,23]]},"references-count":40,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2,2]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2025.60429","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,23]]}}}